- Home
- RHI vs PCVX Comparison
RHI vs PCVX Comparison
Compare RHI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- PCVX
- Stock Information
- Founded
- RHI 1948
- PCVX 2013
- Country
- RHI United States
- PCVX United States
- Employees
- RHI N/A
- PCVX N/A
- Industry
- RHI Professional Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- RHI Consumer Discretionary
- PCVX Health Care
- Exchange
- RHI Nasdaq
- PCVX Nasdaq
- Market Cap
- RHI 4.8B
- PCVX 4.5B
- IPO Year
- RHI N/A
- PCVX 2020
- Fundamental
- Price
- RHI $45.78
- PCVX $32.49
- Analyst Decision
- RHI Hold
- PCVX Strong Buy
- Analyst Count
- RHI 6
- PCVX 10
- Target Price
- RHI $52.50
- PCVX $136.50
- AVG Volume (30 Days)
- RHI 1.1M
- PCVX 2.5M
- Earning Date
- RHI 07-23-2025
- PCVX 05-07-2025
- Dividend Yield
- RHI 5.15%
- PCVX N/A
- EPS Growth
- RHI N/A
- PCVX N/A
- EPS
- RHI 2.01
- PCVX N/A
- Revenue
- RHI $5,671,807,000.00
- PCVX N/A
- Revenue This Year
- RHI N/A
- PCVX N/A
- Revenue Next Year
- RHI $5.39
- PCVX N/A
- P/E Ratio
- RHI $22.84
- PCVX N/A
- Revenue Growth
- RHI N/A
- PCVX N/A
- 52 Week Low
- RHI $40.00
- PCVX $27.66
- 52 Week High
- RHI $78.41
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- RHI 45.87
- PCVX 45.48
- Support Level
- RHI $44.43
- PCVX $31.07
- Resistance Level
- RHI $46.69
- PCVX $33.31
- Average True Range (ATR)
- RHI 1.06
- PCVX 2.06
- MACD
- RHI 0.13
- PCVX 0.66
- Stochastic Oscillator
- RHI 32.85
- PCVX 46.95
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.